Market Research Logo

Streptococcal Infections - Pipeline Review, H1 2016

Streptococcal Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Streptococcal Infections - Pipeline Review, H1 2016’, provides an overview of the Streptococcal Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Streptococcal Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Streptococcal Infections
  • The report reviews pipeline therapeutics for Streptococcal Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Streptococcal Infections therapeutics and enlists all their major and minor projects
  • The report assesses Streptococcal Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Streptococcal Infections
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Streptococcal Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Streptococcal Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Streptococcal Infections Overview
Therapeutics Development
Pipeline Products for Streptococcal Infections - Overview
Pipeline Products for Streptococcal Infections - Comparative Analysis
Streptococcal Infections - Therapeutics under Development by Companies
Streptococcal Infections - Therapeutics under Investigation by Universities/Institutes
Streptococcal Infections - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Streptococcal Infections - Products under Development by Companies
Streptococcal Infections - Products under Investigation by Universities/Institutes
Streptococcal Infections - Companies Involved in Therapeutics Development
Absynth Biologics Limited
AstraZeneca Plc
Centauri Therapeutics Limited
ContraFect Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Merck & Co., Inc.
MGB Biopharma Limited
Sealife PHARMA GMBH
Sequoia Sciences, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Trellis Bioscience, Inc.
Wellstat Vaccines, LLC
Streptococcal Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ATx-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-6142 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EV-035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
firmocidin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
J8-CRM197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGBBP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Group A Streptococcus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Coagulase for Streptococcus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharides for Streptococcal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-295291 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-369926 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcus (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
streptococcus [serotype B] (multivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcus pyogenes (30-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcus pyogenes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcus pyogenes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcus pyogenes vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Streptococcal Infections - Dormant Projects
Streptococcal Infections - Discontinued Products
Streptococcal Infections - Product Development Milestones
Featured News & Press Releases
Aug 25, 2015: Streptococcus Vaccine Developed by UTHSC Professor of Medicine James B. Dale to Begin Clinical Trial
Jun 01, 2015: Researchers create new combination vaccine to fight Streptococcus A
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Streptococcal Infections, H1 2016
Number of Products under Development for Streptococcal Infections - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Streptococcal Infections - Pipeline by Absynth Biologics Limited, H1 2016
Streptococcal Infections - Pipeline by AstraZeneca Plc, H1 2016
Streptococcal Infections - Pipeline by Centauri Therapeutics Limited, H1 2016
Streptococcal Infections - Pipeline by ContraFect Corporation, H1 2016
Streptococcal Infections - Pipeline by Emergent BioSolutions Inc., H1 2016
Streptococcal Infections - Pipeline by GlaxoSmithKline Plc, H1 2016
Streptococcal Infections - Pipeline by Helix BioMedix, Inc., H1 2016
Streptococcal Infections - Pipeline by Merck & Co., Inc., H1 2016
Streptococcal Infections - Pipeline by MGB Biopharma Limited, H1 2016
Streptococcal Infections - Pipeline by Sealife PHARMA GMBH, H1 2016
Streptococcal Infections - Pipeline by Sequoia Sciences, Inc., H1 2016
Streptococcal Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
Streptococcal Infections - Pipeline by Trellis Bioscience, Inc., H1 2016
Streptococcal Infections - Pipeline by Wellstat Vaccines, LLC, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Streptococcal Infections - Dormant Projects, H1 2016
Streptococcal Infections - Dormant Projects (Contd..1), H1 2016
Streptococcal Infections - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Streptococcal Infections, H1 2016
Number of Products under Development for Streptococcal Infections - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report